Jun 12, 2026 08:00AM
Jun 12, 2026 08:00AM
May 18, 2026 08:00AM
May 13, 2026 03:00PM
May 13, 2026 03:00PM
May 11, 2026 08:11PM
May 11, 2026 08:11PM CEL-SCI Corporation Announces Pricing of Public Offering
May 11, 2026 08:00AM
May 11, 2026 08:00AM
Feb 18, 2026 09:00AM
Dec 29, 2025 09:00AM
Aug 29, 2025 12:52PM
Aug 29, 2025 12:52PM
Aug 27, 2025 10:35PM CEL-SCI prices $10 million public offering at $9 per share
Aug 27, 2025 10:35PM
Aug 27, 2025 05:25PM
Aug 27, 2025 05:25PM
Aug 14, 2025 10:45AM
Aug 13, 2025 09:17AM
Aug 13, 2025 09:15AM
Jul 14, 2025 04:07PM CEL-SCI completes $5.7 million stock offering at $3.82 per share
Jul 14, 2025 04:05PM
Jul 11, 2025 12:16PM
Jul 11, 2025 12:16PM
Jul 11, 2025 09:15AM
Jul 11, 2025 09:15AM
Jun 18, 2025 09:00AM
Jun 18, 2025 09:00AM FDA’s Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI’s Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients
May 23, 2025 04:05PM
May 22, 2025 05:44AM
May 21, 2025 08:14PM
May 21, 2025 04:13PM
May 21, 2025 04:05PM
May 21, 2025 08:08AM
May 21, 2025 08:00AM CEL-SCI’s Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia
May 19, 2025 02:40PM
May 19, 2025 02:40PM
May 15, 2025 09:00AM
Apr 23, 2025 08:31AM
Apr 23, 2025 08:30AM
Apr 8, 2025 09:51AM
Mar 24, 2025 09:00AM CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
Mar 18, 2025 04:05PM
Mar 17, 2025 03:24PM
Mar 17, 2025 03:24PM
Mar 17, 2025 08:02AM
Mar 17, 2025 08:00AM
Mar 14, 2025 08:30AM
Feb 20, 2025 08:06AM CEL-SCI Corp (CVM) to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Feb 20, 2025 08:00AM

322,926 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All